Clinical trials: active, in Canada
Corneal Transplantation, Glaucoma
Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Boston keratoprosthesis (KPro) is a piece of specialized plastic that replace sick cornea (transparent structure at the front of the eye) in patients who have failed or those who are expected to have poor results with traditional…
- Trial name
- GDD-KPro (NCT02084745)
- Testing
- Boston keratoprosthesis type 1, Glaucoma drainage device
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life
Prostate cancer, the most frequently diagnosed cancer among occidental men, is associated with a major individual and societal burden.
- Trial name
- RCT-EPA (NCT02333435)
- Testing
- EPA
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- CHU de Quebec-Universite Laval
Chronic Lymphocytic Leukemia
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02970318
- Testing
- Acalabrutinib (ACP-196), Rituximab, Idelalisib
- Where
- 157 sites in United States, Australia and 23 more
- Volunteers
- 310 people
- Sponsor
- Acerta Pharma BV
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
- Trial name
- NCT03233711
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 896 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
High-risk Non-muscle Invasive Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the…
- Trial name
- NCT03711032
- Testing
- Pembrolizumab, BCG
- Where
- 209 sites in United States, Australia and 28 more
- Volunteers
- 1,397 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Ground Glass Opacities (GGOs)
A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study…
- Trial name
- NCT03802981
- Where
- 32 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment…
- Trial name
- ELEVATE UC OLE (NCT03950232)
- Testing
- Etrasimod
- Where
- 472 sites in United States, Argentina and 37 more
- Volunteers
- 896 people
- Sponsor
- Pfizer
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic…
- Trial name
- NCT04269902
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 632 sites in United States, Canada
- Volunteers
- 247 people
- Sponsor
- National Cancer Institute (NCI)
Glaucoma, Corneal Transplantation
Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)
Glaucoma is the most common threat to vision rehabilitation in patients with Boston keratoprosthesis type 1 (KPro) implantation.
- Conditions
- Glaucoma, Corneal Transplantation, Inflammation
- Trial name
- AH-Tears (NCT04339907)
- Testing
- Sampling of tears, Sampling of aqueous humor
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Obesity, Childhood, Insulin Resistance
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose…
- Trial name
- NCT04578652
- Testing
- Metformin 850 mg oral tablet bid, Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University of Alberta
Breast Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer.
- Trial name
- OVELIA (NCT04906395)
- Testing
- TOL2506, Tamoxifen, Letrozole Tablets
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Stem Cell Transplant Complications, Delirium
Delirium in Children Undergoing Stem Cell Transplantation
Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes.
- Trial name
- NCT04937400
- Testing
- Daily screening for delirium
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,040 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05050162
- Testing
- Cisplatin, Computed Tomography, Magnetic Resonance Imaging
- Where
- 370 sites in United States, Canada and 3 more
- Volunteers
- 475 people
- Sponsor
- NRG Oncology
Severe Hemophilia A, Moderate Hemophilia A
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and <70 years…
- Trial name
- Beyond ABR (NCT05181618)
- Testing
- Emicizumab
- Where
- 26 sites in United States, Brazil and 10 more
- Volunteers
- 136 people
- Sponsor
- Hoffmann-La Roche
Neuroendocrine Tumors
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
This study is a single centre non-randomized non-blinded phase II prospective cohort study including 50 participants. The objective of this study is to directly compare 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG activity in patients…
- Trial name
- NCT05255159
- Testing
- 18F-DOPA with furosemide
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Trial name
- SAMURAI (NCT05327686)
- Testing
- Avelumab, Axitinib, Biospecimen Collection
- Where
- 348 sites in United States, Australia and 2 more
- Volunteers
- 240 people
- Sponsor
- NRG Oncology
Biliary Atresia
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia
- Trial name
- BOLD-EXT (NCT05426733)
- Testing
- Odevixibat
- Where
- 30 sites in United States, Australia and 12 more
- Volunteers
- 180 people
- Sponsor
- Albireo, an Ipsen Company
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST (NCT05531565)
- Testing
- Litifilimab
- Where
- 315 sites in United States, Argentina and 28 more
- Volunteers
- 450 people
- Sponsor
- Biogen
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05564390
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice
- Where
- 359 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.